Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fel d 1 is the primary secretoglobin protein and major allergen produced by cats (*Felis catus*), primarily within their sebaceous and salivary glands. In clinical research, particularly in studies sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), purified Fel d 1 is utilized as a standardized biological challenge agent to induce symptoms of allergic rhinitis in sensitized individuals. This application allows for the comparative evaluation of allergen exposure methodologies, such as Nasal Allergen Challenge (NAC) and Environmental Exposure Chambers (EEC). Mechanistically, Fel d 1 triggers allergic responses by cross-linking allergen-specific IgE antibodies bound to the high-affinity FcεRI receptors on the surface of mast cells and basophils, leading to the release of histamine and other inflammatory mediators.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fel d 1.